Insights

Innovative DNA Technologies Elegen specializes in next-generation DNA synthesis and manufacturing, including rapid synthesis of complex DNA and cell-free RNA platforms, presenting opportunities to offer tailored biotech reagents, custom DNA services, and integration solutions for research institutions and biotech companies.

Growing Market Presence With recent high-profile pilot programs and strategic partnerships, Elegen is expanding its influence in personalized medicine and genetic research, opening avenues for collaboration with pharmaceutical firms and personalized therapeutics providers.

Strong Funding and Leadership Backed by $35M in Series B funding and led by a team with a proven track record in biotech innovation, the company presents opportunities for tailored value propositions to investors, innovative biotech startups, and enterprise clients seeking cutting-edge DNA technologies.

Strategic Industry Collaborations Partnerships with companies like Integrated DNA Technologies demonstrate a market shift towards scalable DNA solutions; this provides chances to offer complementary products, joint research initiatives, and co-developments in synthetic biology.

Focus on Personalized Therapeutics Elegen’s development of RNA and DNA platforms for personalized cancer therapeutics indicates a demand for high-quality, customizable genetic materials, creating opportunities to supply reagents, custom constructs, or integrated solutions for biotech and pharma clients engaged in precision medicine.

Similar companies to ELEGEN

ELEGEN Tech Stack

ELEGEN uses 8 technology products and services including NumPy, Docker, Wix, and more. Explore ELEGEN's tech stack below.

  • NumPy
    Advanced Analytics And Data Science
  • Docker
    Containerization
  • Wix
    Content Management System
  • MySQL
    Database
  • Service mesh
    Devops
  • Font Awesome
    Font Scripts
  • HSTS
    Security
  • Django
    Web Frameworks

Media & News

ELEGEN's Email Address Formats

ELEGEN uses at least 1 format(s):
ELEGEN Email FormatsExamplePercentage
First.Last@elegenbio.comJohn.Doe@elegenbio.com
91%
First.MiddleLast@elegenbio.comJohn.MichaelDoe@elegenbio.com
3%
Fir.Last@elegenbio.comJoh.Doe@elegenbio.com
3%
FLast@elegenbio.comJDoe@elegenbio.com
3%

Frequently Asked Questions

What is ELEGEN's official website and social media links?

Minus sign iconPlus sign icon
ELEGEN's official website is elegenbio.com and has social profiles on LinkedInCrunchbase.

What is ELEGEN's SIC code NAICS code?

Minus sign iconPlus sign icon
ELEGEN's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ELEGEN have currently?

Minus sign iconPlus sign icon
As of December 2025, ELEGEN has approximately 91 employees across 4 continents, including North AmericaAfricaEurope. Key team members include Chief Business Officer: D. L. C.Vice President Of Marketing: R. D.Head Of Human Resources: D. E.. Explore ELEGEN's employee directory with LeadIQ.

What industry does ELEGEN belong to?

Minus sign iconPlus sign icon
ELEGEN operates in the Biotechnology Research industry.

What technology does ELEGEN use?

Minus sign iconPlus sign icon
ELEGEN's tech stack includes NumPyDockerWixMySQLService meshFont AwesomeHSTSDjango.

What is ELEGEN's email format?

Minus sign iconPlus sign icon
ELEGEN's email format typically follows the pattern of First.Last@elegenbio.com. Find more ELEGEN email formats with LeadIQ.

How much funding has ELEGEN raised to date?

Minus sign iconPlus sign icon
As of December 2025, ELEGEN has raised $35M in funding. The last funding round occurred on May 14, 2024 for $35M.

When was ELEGEN founded?

Minus sign iconPlus sign icon
ELEGEN was founded in 2017.

ELEGEN

Biotechnology ResearchCalifornia, United States51-200 Employees

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale.

To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity’s greatest challenges.

Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
51-200

Section iconFunding & Financials

  • $35M

    ELEGEN has raised a total of $35M of funding over 4 rounds. Their latest funding round was raised on May 14, 2024 in the amount of $35M.

  • $25M$50M

    ELEGEN's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $35M

    ELEGEN has raised a total of $35M of funding over 4 rounds. Their latest funding round was raised on May 14, 2024 in the amount of $35M.

  • $25M$50M

    ELEGEN's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.